Nonalcoholic fatty liver disease in severely obese adolescent and adult patients

Obesity

Volumn 21, Issue 3, 2013, Pages 591-597

  Holterman, Ai Xuan L ^a   Guzman, Grace ^b   Fantuzzi, Giamila ^c   Wang, Huaping ^a   Aigner, Kristin ^a   Browne, Allen ^a   Holterman, Mark ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIGEN DETECTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INCIDENCE; INFLAMMATION; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SEX RATIO;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HEPATOCYTES; HUMANS; INFLAMMATION MEDIATORS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84876502687     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20174     Document Type: Article

References (40)

1. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-152.
2. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
3. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393.
4. The NS, Suchindran C, North KE, et al. Association of adolescent obesity with risk of severe obesity in adulthood. JAMA 2010; 304: 2042-2047.
5. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
6. Holterman AX, Browne A, Tussing L, et al. A prospective trial for laparoscopic adjustable gastric banding in morbidly obese adolescents: an interim report of weight loss, metabolic and quality of life outcomes. J Pediatr Surg 2010; 45: 74-78; discussion 8-9.
7. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010; 375: 181-183.
8. Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: e500-e503.
9. Kurtoglu S, Akin L, Kendirci M, Hatipoglu N, Elmali F, Mazicioglu M,. The absence of insulin resistance in metabolic syndrome definition leads to underdiagnosing of metabolic risk in obese patients. Eur J Pediatr 2012; 171: 1331-1337.
10. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
11. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330.
12. Schattenberg JM, Schuppan D,. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011; 22: 479-488.
13. Monteiro R, Azevedo I,. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010; 2010.
14. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163.
15. Fierbinteanu-Braticevici C, Baicus C, Tribus L, et al. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointestin Liver Dis 2011; 20: 153-159.
16. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16: 1394-1399.
17. Angulo P,. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology 2011; 53: 1792-1794.
18. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-649.
19. Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44: 458-465.
20. Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809-820.
21. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50: 1113-1120.
22. Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4: 226-232.
23. Brunt EM, Kleiner DE, Behling C, et al. Misuse of scoring systems. Hepatology 2011; 54: 369-370; author reply 70-71.
24. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
25. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004; 109: 3022-3028.
26. Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010; 7: 15.
27. Pepys MB, Hirschfield GM,. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
28. Peri F, Piazza M,. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv 2012; 30: 251-260.
29. Collino M,. High dietary fructose intake: sweet or bitter life? World J Diabetes 2011; 2: 77-81.
30. Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800-809.
31. Cook JS, Hoffman RP, Stene MA, et al. Effects of maturational stage on insulin sensitivity during puberty. J Clin Endocrinol Metab 1993; 77: 725-730.
32. Roemmich JN, Clark PA, Lusk M, et al. Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord 2002; 26: 701-709.
33. Frazier TH, DiBaise JK, McClain CJ,. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr 2011; 35 (5 Suppl): 14S-20S.
34. Kitchens RL, Thompson PA,. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11: 225-229.
35. Nakarai H, Yamashita A, Nagayasu S, Iwashita M, Kumamoto S, Ohyama H, Hata M, Soga Y, Kushiyama A, Asano T, Abiko Y, Nishimura F,. Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications. Innate Immun 2011; 18: 164-170.
36. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211.
37. Schwimmer JB, McGreal N, Deutsch R, et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005; 115: e561-e565.
38. Povel CM, Boer JM, Feskens EJ,. Shared genetic variance between the features of the metabolic syndrome: heritability studies. Mol Genet Metab 2011; 104: 666-669.
39. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
40. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.